<DOC>
	<DOCNO>NCT01132807</DOCNO>
	<brief_summary>This phase II trial study well chemotherapy base positron emission tomography ( PET ) scan work treat patient stage I stage II Hodgkin lymphoma . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Radiation therapy use high energy x-ray kill cancer cell . Giving combination chemotherapy together radiation therapy may kill cancer cell allow doctor save part body cancer start . Comparing result diagnostic procedure , PET scan , do , , chemotherapy may help doctor predict patient 's response treatment help plan best treatment .</brief_summary>
	<brief_title>Chemotherapy Based Positron Emission Tomography Scan Treating Patients With Stage I Stage II Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine progression-free survival ( PFS ) enrollment patient non-bulky stage I II Hodgkin lymphoma . II . To compare PFS patient PET positive versus PET negative follow 2 cycle doxorubicin hydrochloride , bleomycin , vinblastine , dacarbazine ( ABVD ) . SECONDARY OBJECTIVES : I . To evaluate complete response ( CR ) rate patient diagnose non-bulky stage I II Hodgkin lymphoma follow PET response-adapted chemotherapy without radiation therapy . II . To determine predictive value fludeoxyglucose ( FDG ) uptake use various semi-quantitative approach , baseline , 2 cycle AVBD completion therapy . III . To determine predictive value volumetric change compute tomography ( CT ) vs 2-dimensional ( 2-D ) analyse 2 cycle 4 cycle compare PET parameter without combination analysis ( PET + dedicate CT data ) . IV . To compare predictive value metabolic parameters/changes measure visually semi-quantitatively , International Harmonization Project ( IHP ) criterion , 2-D volumetric CT change , molecular parameter , conventional parameter , include International Prognostic Score ( IPS ) . V. To assess whether elevated baseline circulate marker inflammation ( include soluble cluster differentiation CD30 [ sCD ] 30 , soluble CD 163 [ CD163 ] , interleukin-10 ( IL10 ) , chemokine ( C-C motif ) ligand 17 ( CCL17 ) , chemokine ( C-C motif ) ligand 22 [ CCL22 ] ) correlate clinical response PFS PET scan result . VI . To assess whether persistent recurrent elevate serial circulating marker inflammation ( include soluble CD30 [ sCD30 ] , soluble CD163 [ sCD163 ] , IL10 , CCL17 , CCL22 ) correlate relapse/progression PET scan result . VII . To confirm independently useful tissue biomarkers risk stratification patient non-bulky stage I II Hodgkin lymphoma treat regimen . VIII . To compare mediastinal bulk stand posterior-anterior ( PA ) lateral chest x-ray ( &gt; 0.33 maximum chest diameter ) chest CT ( mass &gt; 10 cm ) . OUTLINE : ABVD CHEMOTHERAPY : Patients receive doxorubicin hydrochloride intravenously ( IV ) 3-5 minute , bleomycin sulfate IV 3-5 minute , vinblastine IV 3-5 minute , dacarbazine IV 30 minute day 1 15 . Treatment repeat every 28 day 2 course . Patients undergo PET scan . Patients achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) negative PET scan receive 2 additional course ABVD chemotherapy absence disease progression unacceptable toxicity . Patients achieve CR , PR , SD positive PET scan proceed escalate BEACOPP chemotherapy . ESCALATED BEACOPP* CHEMOTHERAPY : Patients receive doxorubicin hydrochloride IV 3-5 minute cyclophosphamide IV 60 minute day 1 , etoposide IV 45-60 minute day 1-3 , procarbazine orally ( PO ) day 1-7 , prednisone PO day 1-14 , bleomycin sulfate IV vincristine IV day 8 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Within 4-6 week completion BEACOPP chemotherapy , patient undergo involved-field radiotherapy ( IFRT ) 5 day week 3½ week . NOTE : * HIV-positive patient receive standard BEACOPP instead escalate BEACOPP . Patients undergo fludeoxyglucose F^18 PET/CT scan baseline , within 8-10 day completion chemotherapy . Patients also undergo additional PET/CT scan within 3-4 week completion ABVD within 12 week completion BEACOPP IFRT . Patients negative PET scan proceed follow . Patients positive PET scan undergo biopsy** . Patients negative biopsy proceed follow , patient positive biopsy treat discretion investigator . NOTE : ** Patients biopsy neither clinically appropriate medically feasible proceed follow-up . Patients biopsy neither clinically indicate medically appropriate undergo repeat PET/CT scan 3 month . If PET/CT scan remains positive , patient undergo biopsy . After completion study therapy , patient follow every 3 month 1 year , every 6 month 2-3 year , annually maximum 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* Hodgkin lymphoma Clinical stage IA , IB , IIA , IIB disease accord modify Ann Arbor Staging Classification system Subclassified accord WHO modification Rye Classification `` E '' extension allow provide criterion meet NOTE : *Pathology material must submit within 60 day study registration . Coreneedle biopsies acceptable provide contain adequate tissue primary diagnosis immunophenotyping . Fineneedle aspirate allow . If multiple specimen available , submit recent . No nodular lymphocytepredominant Hodgkin lymphoma No mediastinal mass &gt; 0.33 maximum intrathoracic diameter stand posteroanterior chest xray peripheral retroperitoneal adenopathy &gt; 10 cm large diameter Measurable disease physical examination image study Any tumor mass measurable two dimension &gt; 1 cm ( 1.5 cm 0.5 cm slice use , spiral CT scan ) allow Lesions consider intrinsically nonmeasurable include : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Lesions situate previously irradiate area PATIENT CHARACTERISTICS : Performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 100,000/μL Serum creatinine ≤ 2 mg/dL Bilirubin ≤ 2 mg/dL AST ≤ 2 time upper limit normal LVEF normal ECHO MUGA DLCO ≥ 60 % symptomatic pulmonary disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patients know HIV allow provide CD4 count ≥ 350/mcL Patients must multidrug resistant HIV infection ( i.e. , concurrent AIDSdefining condition ) An HIV test require patient history IV drug abuse behavior associate increase risk HIVinfection No `` currently active '' second malignancy nonmelanoma skin cancer Patients consider `` currently active '' malignancy provide complete therapy consider physician &lt; 30 % risk relapse PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy Hodgkin lymphoma 1 course ABVD ( doxorubicin , bleomycin , vinblastine , dacarbazine ) allow consider first course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>